Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812408 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL2239478 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13617075 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL2239474 | 1.00 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL12349810 | 0.99 | ADRB3 (0.41) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3970279 | 0.91 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3970276 | 0.91 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3970285 | 0.91 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8243274 | 0.91 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL7816159 | 0.91 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945641-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-1951743-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2033654-B1 | Process for resolving a mixture of alkyl ester enantiomers using an enzyme | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8003604-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2089020-B1 | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7772183-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7763584-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-27 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2033654-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus | Bristol-Myers Squibb Company (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1629000-B1 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-03 | — | — | US | disclosed |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060257980-A1 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | ADRB3 3491/4885ADRA2B 3677/4885ADRA2C 3435/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | ADRB3 4271/4885ADRA2B 3441/4885ADRA2C 3291/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | ADRB3 4404/4885ADRA2B 3908/4885ADRA2C 3170/4885 |
| US-20080159982-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, VIP | ADRB3 4258/4885ADRA2B 4263/4885ADRA2C 4072/4885 |
| US-20080145334-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, VIP | ADRB3 4258/4885ADRA2B 4263/4885ADRA2C 4072/4885 |
| US-20070093414-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, PYGL | ADRB3 3508/4885ADRA2B 3612/4885ADRA2C 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.